Full Text View
Tabular View
No Study Results Posted
Related Studies
Personal Adherence Evaluation of Medication Use for Adult Bipolar Disorder Patients
This study has been completed.
Study NCT00763581   Information provided by National Institute of Mental Health (NIMH)
First Received: September 19, 2008   Last Updated: February 5, 2009   History of Changes

September 19, 2008
February 5, 2009
April 2008
November 2008   (final data collection date for primary outcome measure)
Subjective Experience of Medication Interview (SEMI) TAD BD, a qualitative instrument modified from the original SEMI [ Time Frame: Measured at a single visit ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00763581 on ClinicalTrials.gov Archive Site
  • Hamilton Rating Scale for Depression (HAM-D) [ Time Frame: Measured at a single visit ] [ Designated as safety issue: No ]
  • Young Mania Rating Scale (YMRS) [ Time Frame: Measured at a single visit ] [ Designated as safety issue: No ]
  • Brief Psychiatric Rating Scale (BPRS) [ Time Frame: Measured at a single visit ] [ Designated as safety issue: No ]
  • Clinical Global Impression for Bipolar Disorder (CGI-BP) [ Time Frame: Measured at a single visit ] [ Designated as safety issue: No ]
Same as current
 
Personal Adherence Evaluation of Medication Use for Adult Bipolar Disorder Patients
Personal Adherence Evaluation of Individuals Receiving Treatment for Bipolar Disorder (PAE in BD)

This study will attempt to increase understanding of why bipolar disorder patients do or do not take their medications by conducting in-depth interviews with them.

Disruptive manic and depressive episodes prevent bipolar disorder (BPD) sufferers from living healthy, functional lives. Relapse rates for BPD are high, between 70% and 90%, with approximately half of those relapses occurring in the first 2 years after remission. High rates of relapse and no substantial improvements in illness outcomes for many patients despite advances in drug treatment may be related to a common problem: medication nonadherence. Nine in 10 individuals with BPD have seriously considered medication withdrawal, and one third of individuals with BDP do not take 30% or more of their prescribed medications. The researchers in this study will identify BPD patients who do not take their medications as prescribed and conduct interviews with them. By obtaining an understanding of subjective reasons for medication nonadherence, this study will pave the way for better interventions to ensure BDP patients take the medications that will help them.

Participation in this study will consist of a single visit, lasting between 1.5 and 3 hours. All participants will have a history of medication nonadherence. Participants will be asked to fill out questionnaires and undergo a structured interview with a researcher. The interview will be audio recorded. The questionnaires and interview will assess BPD symptoms, attitudes toward medications, and to what extent patients are taking their medications. Researchers will also measure the number of pills used in participants' prescriptions by counting how many pills are left in each prescription bottle.

 
Observational
Case-Only, Cross-Sectional
Bipolar Disorder
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
20
January 2009
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of bipolar disorder (BPD) Type I or Type II, as determined by a standardized diagnostic interview, the Mini-International Neuropsychiatric Interview (MINI)
  • Demonstrated history of poor medication adherence, as determined by self-report or clinician report. In this study, self-reported treatment nonadherence will be identified with the Tablet Routines Questionnaire (TRQ). Poorly adherent individuals will be defined as those who miss 30% or more of medication within either the past week or past month (those missing 30% or more within past week will be considered to be non-adherent over the past month). Clinician-assessed nonadherence will be identified via a clinician version of the TRQ to identify nonadherence of 30% or more over the past 30 days.
  • BPD of at least 2 years' duration
  • Treatment with medication to stabilize mood for at least 6 months
  • A Clinical Global Impression (CGI-BP) overall bipolar illness score of 4 or higher

Exclusion Criteria:

  • Unable or unwilling to participate in psychiatric interviews, as based on the clinical opinion of the investigator or the treating clinician
  • High risk of suicide, as seen in factors such as active suicidal ideation, recent suicide attempt, or current suicidal intent or plan
  • Inability to speak English
  • Receiving treatment involuntarily
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00763581
Martha Sajatovic, MD, Case Western Reserve University
R34 MH078967-01, R34 MH078967, DAHBR 96-BHA
National Institute of Mental Health (NIMH)
 
Principal Investigator: Martha Sajatovic, MD Case Western Reserve University
National Institute of Mental Health (NIMH)
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP